Multicentric osteolysis-nodulosis-arthropathy spectrum

Summary

Multicentric osteolysis-nodulosis-arthropathy spectrum (MONDO:0018298) is a disease with 3 cohort genes.

At a glance

• Prevalence: Unknown (Worldwide) [Orphanet-validated]
• Cohort genes: 3
• ClinVar variants: 109
• Phenotypes (HPO): 39

Clinical features

Epidemiology

Prevalence records

1 prevalence record(s), Orphanet:

Type	Class	Value	Geography	Validation
Cases/families		50	Worldwide	Validated

Signs & symptoms

Clinical features (HPO)

39 HPO clinical features (Orphanet curated; top 39 by frequency):

HPO ID	Term	Frequency
HP:0000938	Osteopenia	Very frequent (80-99%)
HP:0000939	Osteoporosis	Very frequent (80-99%)
HP:0001007	Hirsutism	Very frequent (80-99%)
HP:0001369	Arthritis	Very frequent (80-99%)
HP:0001495	Carpal osteolysis	Very frequent (80-99%)
HP:0001999	Abnormal facial shape	Very frequent (80-99%)
HP:0002797	Osteolysis	Very frequent (80-99%)
HP:0003040	Arthropathy	Very frequent (80-99%)
HP:0005922	Abnormal hand morphology	Very frequent (80-99%)
HP:0006234	Osteolysis involving tarsal bones	Very frequent (80-99%)
HP:0009139	Osteolysis involving bones of the lower limbs	Very frequent (80-99%)
HP:0045039	Osteolysis involving bones of the upper limbs	Very frequent (80-99%)
HP:0000248	Brachycephaly	Frequent (30-79%)
HP:0000916	Broad clavicles	Frequent (30-79%)
HP:0001230	Broad metacarpals	Frequent (30-79%)
HP:0001482	Subcutaneous nodule	Frequent (30-79%)
HP:0001626	Abnormality of the cardiovascular system	Frequent (30-79%)
HP:0003312	Abnormal form of the vertebral bodies	Frequent (30-79%)
HP:0005441	Sclerotic cranial sutures	Frequent (30-79%)
HP:0011355	Localized skin lesion	Frequent (30-79%)
HP:0000147	Polycystic ovaries	Occasional (5-29%)
HP:0000315	Abnormality of the orbital region	Occasional (5-29%)
HP:0000612	Iris coloboma	Occasional (5-29%)
HP:0000822	Hypertension	Occasional (5-29%)
HP:0001059	Pterygium	Occasional (5-29%)
HP:0001085	Papilledema	Occasional (5-29%)
HP:0001249	Intellectual disability	Occasional (5-29%)
HP:0001539	Omphalocele	Occasional (5-29%)
HP:0001629	Ventricular septal defect	Occasional (5-29%)
HP:0001631	Atrial septal defect	Occasional (5-29%)
HP:0001634	Mitral valve prolapse	Occasional (5-29%)
HP:0001647	Bicuspid aortic valve	Occasional (5-29%)
HP:0001678	Atrioventricular block	Occasional (5-29%)
HP:0001680	Coarctation of aorta	Occasional (5-29%)
HP:0001719	Double outlet right ventricle	Occasional (5-29%)
HP:0002659	Increased susceptibility to fractures	Occasional (5-29%)
HP:0005994	Nodular goiter	Occasional (5-29%)
HP:0010314	Premature thelarche	Occasional (5-29%)
HP:0100651	Type I diabetes mellitus	Occasional (5-29%)

Identifiers

Disease identifiers

Field	Value
Canonical name	multicentric osteolysis-nodulosis-arthropathy spectrum
Mondo ID	MONDO:0018298
Orphanet	371428
SNOMED CT	716868003
UMLS	C1850155
MedGen	342428
GARD	0017610
Is cancer (heuristic)	no

Also known as: MONA spectrum

Data availability: 109 ClinVar variants · 2 GenCC gene-disease records · 1 cell line.

Disease family

An umbrella term covering 2 Mondo subtypes.

Classification path: disease › human disease › disease by etiologic mechanism › disease of genetic or genomic mechanism › hereditary disease › skeletal dysplasia › primary osteolysis › multicentric osteolysis-nodulosis-arthropathy spectrum

Related subtypes (13): acroosteolysis, multicentric carpo-tarsal osteolysis with or without nephropathy, pacman dysplasia, familial expansile osteolysis, Hutchinson-Gilford progeria syndrome, polycystic lipomembranous osteodysplasia with sclerosing leukoencephaly, hyaline fibromatosis syndrome, autosomal recessive distal osteolysis syndrome, Paget disease of bone 2, early-onset, talo-patello-scaphoid osteolysis, Nestor-Guillermo progeria syndrome, mandibuloacral dysplasia, phalangeal microgeodic syndrome

Subtypes (2): multicentric osteolysis, nodulosis, and arthropathy, Winchester syndrome

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

ClinVar germline variants

109 retrieved; paginated sample, class counts are floors:

46 uncertain significance, 25 benign, 18 conflicting classifications of pathogenicity, 8 pathogenic, 5 likely benign, 4 benign/likely benign, 3 likely pathogenic

ClinVar	Variant (HGVS)	Gene	Classification	Review
625853	NM_017839.5(LPCAT2):c.172-6188G>A	LPCAT2	Pathogenic	no assertion criteria provided
1332689	NM_004530.6(MMP2):c.910_916del (p.Ser304fs)	MMP2	Pathogenic	criteria provided, single submitter
1332865	NM_004530.6(MMP2):c.789C>A (p.Tyr263Ter)	MMP2	Pathogenic	criteria provided, single submitter
1341994	NM_004530.6(MMP2):c.301C>T (p.Arg101Cys)	MMP2	Pathogenic	criteria provided, single submitter
1685950	NM_004530.6(MMP2):c.691G>T (p.Glu231Ter)	MMP2	Pathogenic	criteria provided, single submitter
17109	NM_004530.6(MMP2):c.732C>A (p.Tyr244Ter)	MMP2	Pathogenic	criteria provided, multiple submitters, no conflicts
198809	NM_004530.6(MMP2):c.1287del (p.Asn430fs)	MMP2	Pathogenic	criteria provided, multiple submitters, no conflicts
915430	NM_004530.6(MMP2):c.1648C>T (p.Arg550Ter)	MMP2	Pathogenic	criteria provided, single submitter
1299550	NM_004530.6(MMP2):c.529G>A (p.Glu177Lys)	MMP2	Likely pathogenic	criteria provided, single submitter
1299551	NM_004530.6(MMP2):c.1456TTC[2] (p.Phe488del)	MMP2	Likely pathogenic	criteria provided, single submitter
1332856	NM_004530.6(MMP2):c.306C>A (p.Cys102Ter)	MMP2	Likely pathogenic	criteria provided, single submitter
194059	NM_004530.6(MMP2):c.1858G>A (p.Val620Ile)	MMP2	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
198174	NM_004530.6(MMP2):c.932C>T (p.Thr311Met)	MMP2	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
283518	NM_004530.6(MMP2):c.759C>T (p.Ser253=)	MMP2	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
319747	NM_004530.6(MMP2):c.588C>T (p.Ala196=)	MMP2	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
319748	NM_004530.6(MMP2):c.658+10G>A	MMP2	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
319749	NM_004530.6(MMP2):c.658+13C>T	MMP2	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
319757	NM_004530.6(MMP2):c.1233G>A (p.Leu411=)	MMP2	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
319758	NM_004530.6(MMP2):c.1336+11G>A	MMP2	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
319763	NM_004530.6(MMP2):c.1572C>T (p.Tyr524=)	MMP2	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
319767	NM_004530.6(MMP2):c.1779G>A (p.Glu593=)	MMP2	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
714021	NM_004530.6(MMP2):c.1860C>T (p.Val620=)	MMP2	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
729361	NM_004530.6(MMP2):c.96G>T (p.Ser32=)	MMP2	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
732303	NM_004530.6(MMP2):c.1842C>T (p.Pro614=)	MMP2	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
885135	NM_004530.6(MMP2):c.306C>T (p.Cys102=)	MMP2	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
885200	NM_004530.6(MMP2):c.1551G>A (p.Pro517=)	MMP2	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
885201	NM_004530.6(MMP2):c.1560T>C (p.Ile520=)	MMP2	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
886041	NM_004530.6(MMP2):c.813C>T (p.Tyr271=)	MMP2	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
887036	NM_004530.6(MMP2):c.969C>T (p.Tyr323=)	MMP2	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
1029860	NM_004530.6(MMP2):c.628G>T (p.Asp210Tyr)	MMP2	Uncertain significance	criteria provided, single submitter

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 8 · Orphanet: 2 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

GenCC gene–disease validity (cohort genes)

the Disease column is the GenCC-asserted condition — a cohort gene’s strongest validity may be for a related predisposition syndrome.

Gene	Classification	Inheritance	Disease	Records
MMP2	Strong	Autosomal recessive	multicentric osteolysis, nodulosis, and arthropathy	4
MMP14	Supportive	Autosomal recessive	multicentric osteolysis-nodulosis-arthropathy spectrum	4

Orphanet rare-disease linkage (cohort genes)

Gene	Orphanet ID	Rare disease
MMP2	Orphanet:371428	Multicentric osteolysis-nodulosis-arthropathy spectrum
MMP14	Orphanet:371428	Multicentric osteolysis-nodulosis-arthropathy spectrum

Cohort genes → proteins

3 cohort genes, 3 distinct canonical proteins.

Evidence partition

Subset	Genes
multi_evidence	3

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
MMP2	HGNC:7166	ENSG00000087245	P08253	72 kDa type IV collagenase	gencc,clinvar
MMP14	HGNC:7160	ENSG00000157227	P50281	Matrix metalloproteinase-14	gencc
LPCAT2	HGNC:26032	ENSG00000087253	Q7L5N7	Lysophosphatidylcholine acyltransferase 2	clinvar

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
MMP2	72 kDa type IV collagenase	Ubiquitinous metalloproteinase that is involved in diverse functions such as remodeling of the vasculature, angiogenesis, tissue repair, tumor invasion, inflammation, and atherosclerotic plaque rupture.
MMP14	Matrix metalloproteinase-14	Endopeptidase that degrades various components of the extracellular matrix such as collagen.
LPCAT2	Lysophosphatidylcholine acyltransferase 2	Exhibits both acyltransferase and acetyltransferase activities.

Protein-family classification

Druggable: 3 · Difficult: 0 · Unknown: 0 · Druggable fraction: 1.0

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Protease	2	24.4×	0.004
Enzyme (other)	1	4.0×	0.230

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
MMP2	Protease	yes	3.4.24.24	FN_type2_dom, Hemopexin-like_dom, Pept_M10_metallopeptidase
MMP14	Protease	yes	3.4.24.80	Hemopexin-like_dom, Pept_M10_metallopeptidase, Peptidoglycan-bd-like
LPCAT2	Enzyme (other)	yes	2.3.1.23	EF_hand_dom, Plipid/glycerol_acylTrfase, EF-hand-dom_pair

Expression context

Cohort genes with no expression data: 0.

3 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	0
broad (>20)	3
unknown	0

Top tissues across cohort

Tissue	Cohort genes
gall bladder	2
mucosa of stomach	2
stromal cell of endometrium	2
caput epididymis	1
left lobe of thyroid gland	1
thyroid gland	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
MMP2	262	ubiquitous	marker	stromal cell of endometrium, gall bladder, mucosa of stomach
MMP14	236	ubiquitous	marker	stromal cell of endometrium, mucosa of stomach, gall bladder
LPCAT2	241	ubiquitous	marker	caput epididymis, left lobe of thyroid gland, thyroid gland

Protein interactions among cohort

Intra-cohort edges: 1.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
MMP2	4,603
MMP14	2,822
LPCAT2	1,653

Intra-cohort edges

A	B	Sources
MMP14	MMP2	string_interaction

Structural data

PDB: 2 · AlphaFold-only: 1 · No structure: 0

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
MMP2	P08253	14
MMP14	P50281	12

AlphaFold-only cohort genes (top 30 by pLDDT)

Symbol	UniProt	pLDDT
LPCAT2	Q7L5N7	82.05

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 28. Enrichment computed across 3 evidence-associated genes (3 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 3 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
Activation of Matrix Metalloproteinases	2	205.8×	9e-04	MMP2, MMP14
Collagen degradation	2	117.1×	0.001	MMP2, MMP14
Degradation of the extracellular matrix	2	78.5×	0.002	MMP2, MMP14
Extracellular matrix organization	2	42.1×	0.005	MMP2, MMP14
TGFBR3 PTM regulation	1	317.2×	0.018	MMP14
Acyl chain remodelling of PC	1	141.0×	0.032	LPCAT2
Signaling by TGFBR3	1	122.8×	0.032	MMP14
Response of endothelial cells to shear stress	1	100.2×	0.035	MMP14
Cellular responses to mechanical stimuli	1	86.5×	0.036	MMP14
EPH-ephrin mediated repulsion of cells	1	73.2×	0.038	MMP2
Extra-nuclear estrogen signaling	1	56.8×	0.040	MMP2
EPH-Ephrin signaling	1	55.2×	0.040	MMP2
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells	1	53.6×	0.040	MMP14
MAPK6/MAPK4 signaling	1	45.3×	0.043	MMP2
ESR-mediated signaling	1	42.8×	0.043	MMP2
Signaling by TGFB family members	1	38.5×	0.043	MMP14
Interleukin-4 and Interleukin-13 signaling	1	34.3×	0.043	MMP2
Signaling by Nuclear Receptors	1	34.0×	0.043	MMP2
Signal Transduction	2	6.8×	0.043	MMP2, MMP14
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)	1	28.8×	0.048	MMP2
Signaling by Interleukins	1	21.4×	0.061	MMP2
Axon guidance	1	15.1×	0.083	MMP2
Nervous system development	1	14.3×	0.083	MMP2
Cytokine Signaling in Immune system	1	13.6×	0.084	MMP2
Cellular responses to stimuli	1	10.5×	0.103	MMP14
Developmental Biology	1	4.8×	0.208	MMP2
Immune System	1	4.3×	0.222	MMP2
Metabolism of proteins	1	4.1×	0.223	MMP2

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 3 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
tissue remodeling	2	864.2×	1e-04	MMP2, MMP14
endodermal cell differentiation	2	330.4×	3e-04	MMP2, MMP14
ovarian follicle development	2	261.3×	3e-04	MMP2, MMP14
collagen catabolic process	2	261.3×	3e-04	MMP2, MMP14
extracellular matrix disassembly	2	244.2×	3e-04	MMP2, MMP14
response to estrogen	2	229.3×	3e-04	MMP2, MMP14
response to mechanical stimulus	2	200.6×	3e-04	MMP2, MMP14
protein catabolic process	2	158.2×	5e-04	MMP2, MMP14
negative regulation of GDF15-GFRAL signaling pathway	1	5617.3×	0.001	MMP14
extracellular matrix organization	2	81.4×	0.001	MMP2, MMP14
response to hypoxia	2	63.8×	0.002	MMP2, MMP14
cellular response to genistein	1	2808.7×	0.002	MMP14
positive regulation of macrophage migration	1	1872.4×	0.003	MMP14
platelet activating factor biosynthetic process	1	1404.3×	0.003	LPCAT2
positive regulation of oxidative stress-induced neuron intrinsic apoptotic signaling pathway	1	1404.3×	0.003	MMP2
angiogenesis	2	41.6×	0.003	MMP2, MMP14
positive regulation of cell migration	2	41.1×	0.003	MMP2, MMP14
intramembranous ossification	1	936.2×	0.004	MMP2
response to odorant	1	936.2×	0.004	MMP14
blood vessel maturation	1	802.5×	0.004	MMP2
astrocyte cell migration	1	802.5×	0.004	MMP14
trophoblast cell migration	1	802.5×	0.004	MMP2
peripheral nervous system axon regeneration	1	702.2×	0.004	MMP2
bone trabecula formation	1	702.2×	0.004	MMP2
ovulation from ovarian follicle	1	624.1×	0.004	MMP2
luteinization	1	624.1×	0.004	MMP2
parturition	1	624.1×	0.004	MMP2
prostate gland epithelium morphogenesis	1	624.1×	0.004	MMP2
negative regulation of vasoconstriction	1	561.7×	0.004	MMP2
craniofacial suture morphogenesis	1	561.7×	0.004	MMP14

Therapeutics

Drug target analysis

Approved (phase 4): 2 · Phase ≥3: 2 · Phased (≥1): 2 · Undrugged: 1

Druggability breadth: 2 of 3 evidence-associated genes (67%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Genes with an approved drug

The molecule shown is one approved compound that hits the gene — not necessarily a drug of choice or one indicated for this disease.

Symbol	Example approved molecule
MMP2	DOXYCYCLINE
MMP14	CHLOROXINE

Top cohort targets by molecule count

Symbol	Molecules	Max phase
MMP2	26	4
MMP14	13	4
LPCAT2	0	0

Drugs targeting cohort genes (top 30)

Molecule	Max phase	Targets in cohort
DOXYCYCLINE	4	MMP2
TILUDRONIC ACID	4	MMP14, MMP2
DAUNORUBICIN	4	MMP2
ZOLEDRONIC ACID	4	MMP14, MMP2
DOXORUBICIN	4	MMP2
CHLORHEXIDINE	4	MMP2
CHLOROXINE	4	MMP14
CLIOQUINOL	4	MMP14
CAFFEIC ACID	3	MMP2
MEDRONIC ACID	3	MMP2
MARIMASTAT	3	MMP14, MMP2
EPIGALOCATECHIN GALLATE	3	MMP14, MMP2
QUERCETIN	3	MMP2
ACLARUBICIN	3	MMP2
PRINOMASTAT	3	MMP14, MMP2
CIPEMASTAT	2	MMP14, MMP2
LUTEOLIN	2	MMP2
ILOMASTAT	2	MMP14, MMP2
TOSEDOSTAT	2	MMP2
SOLIMASTAT	2	MMP2
TANOMASTAT	2	MMP2
BATIMASTAT	2	MMP14, MMP2
UBENIMEX	2	MMP2
CTS-1027	2	MMP14, MMP2
ALDUMASTAT	2	MMP14, MMP2
REBIMASTAT	2	MMP14, MMP2
S-3304	1	MMP2
AGG-523	1	MMP2

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 3.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

Symbol	Assays	Type breakdown
MMP2	771	Binding:735, ADMET:28, Functional:7, Unclassified:1
MMP14	274	Binding:252, ADMET:18, Functional:3, Toxicity:1

Cohort enzymes (BRENDA EC)

Symbol	EC numbers	Names
MMP2	3.4.24.24	gelatinase A
MMP14	3.4.24.80, 3.4.24.B5	membrane-type matrix metalloproteinase-1,
LPCAT2	2.3.1.23, 2.3.1.51, 2.3.1.67	1-acylglycerophosphocholine O-acyltransferase, 1-acylglycerol-3-phosphate O-acyltransferase, 1-alkylglycerophosphocholine O-acetyltransferase

Cohort genes with high screening signal

≥100 ChEMBL assays — a studied-ness signal; see Therapeutics for approved-drug status.

Symbol	ChEMBL assays
MMP2	771
MMP14	274

Pharmacogenomics

Cohort genes with a PharmGKB record: 3; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

28 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Compound	Max phase	Cohort target (bioactivity)
DOXYCYCLINE	4	MMP2
TILUDRONIC ACID	4	MMP14, MMP2
DAUNORUBICIN	4	MMP2
ZOLEDRONIC ACID	4	MMP14, MMP2
DOXORUBICIN	4	MMP2
CHLORHEXIDINE	4	MMP2
CHLOROXINE	4	MMP14
CLIOQUINOL	4	MMP14
CAFFEIC ACID	3	MMP2
MEDRONIC ACID	3	MMP2
MARIMASTAT	3	MMP14, MMP2
EPIGALOCATECHIN GALLATE	3	MMP14, MMP2
QUERCETIN	3	MMP2
ACLARUBICIN	3	MMP2
PRINOMASTAT	3	MMP14, MMP2
CIPEMASTAT	2	MMP14, MMP2
LUTEOLIN	2	MMP2
ILOMASTAT	2	MMP14, MMP2
TOSEDOSTAT	2	MMP2
SOLIMASTAT	2	MMP2
TANOMASTAT	2	MMP2
BATIMASTAT	2	MMP14, MMP2
UBENIMEX	2	MMP2
CTS-1027	2	MMP14, MMP2
ALDUMASTAT	2	MMP14, MMP2
REBIMASTAT	2	MMP14, MMP2
S-3304	1	MMP2
AGG-523	1	MMP2

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	2	MMP2, MMP14
B	Phased (≥1) drug, not yet approved	0
C	Druggable family + PDB, no drug	0
D	Druggable family + AlphaFold only, no drug	1	LPCAT2
E	Difficult family or no structure, no drug	0

Undrugged target profiles

1 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Symbol	ChEMBL assays	Drugged partners (top 3)
LPCAT2	0	—

Clinical trials & evidence

Clinical trials

Clinical trials: 0.